How to Get Lantus (Insulin Glargine) in Oregon

What Is Lantus and Why Oregon Patients Need a Prescription

Lantus is a recombinant long-acting basal insulin that covers background glucose needs for roughly 24 hours after a single subcutaneous injection. The FDA approved the original insulin glargine formulation in April 2000, and the current U.S. prescribing information designates it as a prescription-only product for adults and pediatric patients aged 6 years and older with type 1 or type 2 diabetes. 1

Insulin glargine works by binding the insulin receptor with a duration roughly equivalent to 24 hours, producing a flat, peakless pharmacokinetic profile that reduces nocturnal hypoglycemia risk compared with NPH insulin. A 2009 meta-analysis in Diabetologia (N=2,304 patients across five randomized controlled trials) confirmed that glargine produced significantly fewer nocturnal hypoglycemic events than NPH (relative risk 0.57 to 95% CI 0.48 to 0.67, P<0.001). 2

In Oregon, approximately 320,000 adults live with diagnosed diabetes according to Oregon Health Authority surveillance data. 3 That population relies on basal insulin to maintain glycemic targets recommended by the American Diabetes Association: an HbA1c below 7.0% for most non-pregnant adults, with individualized targets for older or frail patients. 4

Oregon requires a valid prescriber-patient relationship before any Schedule-exempt controlled substance or prescription drug can be dispensed. Insulin glargine falls into that category. The good news is that both traditional office visits and synchronous telehealth encounters satisfy that requirement under Oregon Revised Statutes. 5

Who Can Prescribe Lantus in Oregon

Any licensed prescriber with an active Oregon DEA registration and the authority to prescribe prescription drugs can write for Lantus. That includes physicians (MD and DO), nurse practitioners (NP) with prescriptive authority, physician assistants (PA), and clinical pharmacists operating under a collaborative practice agreement with a supervising physician.

Oregon grants full practice authority to certified nurse practitioners under ORS 678.375. An NP does not need physician oversight to prescribe insulin glargine independently, making NP-led telehealth visits a practical access point for many patients. PAs in Oregon prescribe under a delegation agreement with a supervising physician, but that agreement is widespread across primary care and endocrinology clinics. 6

Endocrinologists manage the most complex insulin regimens, but the American Association of Clinical Endocrinology 2023 diabetes guidelines note that primary care clinicians can safely initiate and titrate basal insulin in type 2 diabetes using a simple fasting glucose-titration protocol (adjust dose by 2 units every 3 days until fasting glucose is 80 to 130 mg/dL). 7

For type 1 diabetes, referral to an endocrinologist or diabetes care and education specialist is preferred at initiation. The ADA 2024 Standards of Care state: "People with type 1 diabetes should be evaluated by an endocrinologist or an endocrinology team at diagnosis and periodically thereafter to optimize glycemic management." 4

Telehealth Options for a Lantus Prescription in Oregon

Oregon telehealth prescribing for non-controlled medications is fully permitted. Oregon law (ORS 677.060) allows a prescriber-patient relationship to be established via synchronous audio-video telehealth, which is the standard approach used by most national and regional platforms. No in-person visit is required before an online provider can prescribe insulin glargine.

Several national telehealth platforms hold active Oregon medical licenses and routinely prescribe basal insulin. A typical workflow runs as follows. The patient completes an intake form documenting diabetes type, current medications, most recent HbA1c, and fasting glucose logs. A licensed Oregon prescriber reviews the record and conducts a video or phone visit. If the clinical picture is appropriate, the prescription is sent electronically to the patient's preferred Oregon pharmacy, usually within the same business day. 8

The HealthRX clinical team uses a four-step telehealth-to-pharmacy framework for new Oregon patients seeking basal insulin:

1. Pre-visit labs: fasting glucose, HbA1c, basic metabolic panel (BMP), and a recent weight.
2. Video intake visit (15 to 30 minutes) to confirm diabetes type, prior insulin history, injection technique comfort, and hypoglycemia risk factors.
3. Prescription transmission to the patient's chosen Oregon pharmacy, with initial dose set at 0.1 to 0.2 units/kg/day or 10 units once daily, whichever is lower.
4. Follow-up message or call at 72 hours to review fasting glucose log and adjust dose.

Research published in Diabetes Care (2021) found that patients who received telehealth-initiated basal insulin titration achieved comparable HbA1c reductions to in-person titration groups at 12 weeks (mean reduction 1.4% vs. 1.3%, P<0.001). 8

Oregon telehealth visits are covered by most commercial insurers and by Oregon Health Plan (OHP) Medicaid for established diabetes management visits. Patients should confirm their plan's telehealth cost-sharing before booking. 9

Labs Needed Before Starting Lantus in Oregon

A prescriber will typically require recent lab work before initiating or continuing insulin glargine. The minimum panel for a new Lantus prescription includes HbA1c (to confirm diagnosis and assess current control), a fasting plasma glucose, a basic metabolic panel (serum creatinine, electrolytes, eGFR), and a complete blood count if not done in the prior 12 months.

HbA1c alone confirms the diagnosis of diabetes at 6.5% or above on two separate occasions, per ADA 2024 criteria. 4 Renal function matters because insulin clearance slows as eGFR falls, increasing hypoglycemia risk; the ADA recommends assessing kidney function at diagnosis and at least annually thereafter. 10

For type 1 diabetes specifically, a C-peptide level and GAD65 antibody panel help confirm autoimmune etiology and distinguish type 1 from LADA or type 2 disease. These tests inform whether basal-only or basal-bolus therapy is appropriate. The Endocrine Society clinical practice guideline on type 1 diabetes (2021) recommends C-peptide testing when diabetes classification is uncertain. 11

Thyroid function (TSH) is reasonable at baseline for type 1 patients given the elevated coexistence of autoimmune thyroid disease. Labs do not need to be drawn the same day as the telehealth visit; results uploaded to a secure patient portal within 48 hours of the visit are generally sufficient for most Oregon telehealth providers.

Oregon Medicaid (OHP) Coverage and Prior Authorization

Oregon Health Plan covers insulin glargine for both type 1 and type 2 diabetes, but requires prior authorization (PA) before dispensing. The PA process is managed through the patient's coordinated care organization (CCO) or their pharmacy benefit manager.

For type 1 diabetes, PA approval is nearly automatic when the prescriber documents the diagnosis with an ICD-10 code of E10.x and confirms that the patient requires insulin to survive. Most Oregon CCOs approve type 1 PA requests within one business day. 12

For type 2 diabetes, PA criteria typically require documentation that the patient has tried at least one oral antidiabetic agent (usually metformin), that glycemic control remains inadequate (HbA1c above 8.0% or fasting glucose consistently above 180 mg/dL), and that basal insulin is medically necessary. The prescriber completes OHA Form 3413 or the CCO-specific PA form. Approval generally takes 3 to 5 business days. 12

Sanofi's Insulins Valyou Savings Program and the Walmart ReliOn brand insulin glargine (available over the counter in Oregon at $25 per vial) provide fallback options if PA is delayed or denied. Biosimilar interchangeable products, Semglee (insulin glargine-yfgn) and Rezvoglar, received FDA interchangeable designations in 2021 and 2022 respectively, meaning Oregon pharmacists may substitute them for Lantus without contacting the prescriber unless the prescription is marked "dispense as written." 13

Long-Term Safety: The ORIGIN Trial

The ORIGIN trial (Outcome Reduction with an Initial Glargine Intervention) enrolled 12,537 patients with dysglycemia (impaired fasting glucose, impaired glucose tolerance, or early type 2 diabetes) and randomized them to insulin glargine or standard care. Over a median follow-up of 6.2 years, glargine did not increase the rate of the primary composite cardiovascular endpoint (HR 1.02 to 95% CI 0.94 to 1.11, P=0.63). 14

The ORIGIN investigators also reported that glargine produced a median HbA1c of 6.2% in the intervention group versus 6.6% in the standard care group, with a modest but statistically significant increase in confirmed hypoglycemia (1.00 vs. 0.31 episodes per patient-year, P<0.001). Weight gain with glargine averaged 1.6 kg over the trial period. 14

These findings reassure prescribers and patients that long-term basal insulin use does not carry an elevated cardiovascular risk, a concern that had been raised in earlier observational data. The trial also established that targeting near-normal fasting glucose with glargine is achievable without excess hypoglycemia in most patients, provided dose titration follows the guidelines. 15

A 2022 Cochrane systematic review of basal insulin analogs (N=29 trials, 8,784 participants) confirmed that insulin glargine U-100 reduces HbA1c by approximately 1.0 to 1.5 percentage points from baseline when used as basal insulin in type 2 diabetes, with consistent results across sub-groups defined by baseline HbA1c, age, and duration of diabetes. 16

Dosing and Titration Protocol for Oregon Patients

The FDA-approved starting dose for insulin-naive type 2 diabetes patients is 0.1 to 0.2 units/kg body weight once daily, or a flat 10 units once daily. Either approach is acceptable. The injection is given at the same time each day, subcutaneously into the abdomen, thigh, or upper arm; site rotation reduces lipohypertrophy. 1

The standard fasting glucose titration algorithm validated in the LANMET trial (2006, N=110) and the AT.LANTUS trial (2009, N=4,961) adjusts the dose upward by 2 units every 3 days when the mean of three consecutive fasting glucose readings exceeds 130 mg/dL. 17 18 The dose is held or reduced if any fasting glucose reading falls below 80 mg/dL or any symptomatic hypoglycemia episode occurs.

For type 1 diabetes, basal insulin typically provides 40 to 50% of total daily insulin requirements. The remainder comes from prandial rapid-acting insulin. A starting basal dose of 0.2 units/kg once daily is common, with careful upward titration guided by fasting glucose and continuous glucose monitor (CGM) data. The ADA recommends CGM for all adults with type 1 diabetes regardless of treatment regimen. 4

Insulin glargine U-300 (Toujeo) offers a higher concentration formulation for patients requiring large doses or those experiencing injection-site reactions with U-100; Oregon pharmacies carry both formulations. Biosimilar glargine products carry identical dosing instructions and may be dispensed interchangeably per FDA guidance. 13

Transferring an Existing Lantus Prescription to Oregon

Patients moving to Oregon from another state, or snowbirds managing care across state lines, can transfer their existing Lantus prescription to an Oregon-licensed pharmacy. Federal law (21 USC 353) and Oregon Board of Pharmacy rules allow a pharmacist to accept a transferred prescription from another state, provided the prescription has remaining refills and the prescribing provider holds an active license in their originating state. 19

The receiving Oregon pharmacy contacts the dispensing pharmacy in the originating state and records the transfer. This process takes 15 to 30 minutes at most chain pharmacies. If the prescription has no remaining refills, the patient needs a new prescription from an Oregon-licensed provider. A telehealth visit typically resolves this within the same day. 20

Oregon pharmacists cannot write new insulin glargine prescriptions independently, but they may authorize emergency short-term supplies (up to a 72-hour emergency supply) under ORS 689.515 when the patient is at risk of therapeutic interruption and the prescriber cannot be reached promptly. This emergency dispensing provision is particularly useful for patients whose prior-authorization approval is delayed during a state transfer. 21

503A Compounding Pharmacies in Oregon

Oregon-licensed 503A compounding pharmacies may prepare insulin glargine for individual patients with a valid prescription when a commercially manufactured product is unavailable, when the patient requires a non-standard concentration, or when a documented allergy to an excipient in the commercial product exists. The FDA distinguishes 503A pharmacies (patient-specific compounding) from 503B outsourcing facilities (larger-scale compounding); both operate under federal oversight but follow different sets of rules. 22

Compounded insulin glargine is not a direct substitute for FDA-approved Lantus in terms of regulatory equivalence. The Oregon Board of Pharmacy requires that compounding be performed only when a commercially available product is not suitable for the individual patient. Prescribers should document the medical necessity for compounded insulin glargine in the patient's chart. 23

Shipping of compounded prescription insulin from a 503A pharmacy to an Oregon patient is permitted when the pharmacy holds an Oregon non-resident pharmacy permit or an in-state license and complies with cold-chain shipping requirements (2 to 8 degrees Celsius during transit). Most major Oregon 503A pharmacies use overnight cold-pack shipping for insulin products.

How Long Until You Receive Lantus in Oregon

Most Oregon patients receive their first Lantus supply within 24 to 72 hours of an electronically transmitted prescription. Large retail chains including Walgreens, CVS, and Rite Aid maintain insulin glargine in stock at the vast majority of Oregon locations. Smaller independent pharmacies in rural Oregon may require a 24-hour special order.

Mail-order pharmacy services affiliated with Oregon Health Plan or commercial insurers typically ship a 90-day supply within 3 to 7 business days. Prior authorization adds 1 to 5 business days on average. Patients needing insulin urgently while PA is pending should ask their prescriber for a "bridge prescription" for a 30-day supply at cash pay, or request the emergency 72-hour dispensing provision described above. 12

Cold storage is required from the pharmacy to home. Unopened Lantus vials and pens are stored in a refrigerator at 36 to 46 degrees Fahrenheit. Once opened or if stored at room temperature, Lantus vials are stable for 28 days and Lantus SoloStar pens for 28 days, per the current FDA label. 1

Cost and Savings Programs Available to Oregon Patients

Lantus carries a list price of approximately $300 to $330 per vial before discounts. Oregon patients have several cost-reduction options. Sanofi's Insulins Valyou Savings Program caps out-of-pocket cost at $99 per 30-day supply for eligible commercially insured patients. The Sanofi Patient Assistance Program (Insulins Valyou PAP) provides free insulin to uninsured patients with household income at or below 400% of the federal poverty level. 24

The American Diabetes Association 2024 Standards of Care state: "Clinicians should proactively inform patients about lower-cost insulin options, insulin-assistance programs, and pharmacy coupons when prescribing insulin." 4 GoodRx and similar coupon platforms routinely bring Lantus to $80 to $120 per vial at Oregon pharmacies, and biosimilar glargine (Semglee) routinely lists below $60 per vial with coupons. 25

Oregon Health Plan members who qualify for Medicaid pay $0 to $4 per prescription after PA approval, depending on CCO formulary tier. Medicare Part D beneficiaries are subject to the Inflation Reduction Act insulin cap of $35 per month for covered insulin products including Lantus, effective January 2023. 26

Monitoring and Follow-Up After Starting Lantus

After initiation, the prescriber will schedule follow-up at 2 to 4 weeks to review fasting glucose logs and adjust the dose. HbA1c should be checked at 3 months to assess overall glycemic response. A complete metabolic panel at 3 to 6 months assesses renal function as dose titration proceeds.

Patients should recognize the symptoms of hypoglycemia: sweating, tremor, palpitations, confusion, and hunger occurring when blood glucose falls below 70 mg/dL. The ADA defines clinically significant hypoglycemia as any reading below 54 mg/dL, which requires immediate treatment with 15 grams of fast-acting carbohydrate. 4

The risk of hypoglycemia increases with renal impairment (eGFR <45 mL/min/1.73m2), irregular meals, increased physical activity, alcohol use, and concurrent use of sulfonylureas or other insulin secretagogues. Oregon prescribers should review concurrent medications at every follow-up visit and reduce basal insulin dose preemptively when any of these risk factors change. 27

Continuous glucose monitoring reduces severe hypoglycemia rates by 53% in adults with type 1 diabetes compared with self-monitored blood glucose alone, per the DIAMOND trial (N=158 to 24 weeks). 28 Oregon Medicaid covers CGM for type 1 diabetes without PA; type 2 patients on basal insulin may require PA depending on their CCO.